07.09.15
Charles River will acquire Celsis International, Ltd. A purchase price was not disclosed. The transaction is expected to be completed during the third quarter.
According to Jay LeCoque, CEO, Celsis International, Ltd, Celsis is a complement to Charles River's Endotoxin and Microbial Detection group, creating the most comprehensive solution for rapid quality control testing of biopharmaceutical and consumer products. Specifically, the addition of Celsis, with its Advance II, Accel and Innovate systems will complement Charles River's recently introduced PTS-Micro, a rapid bioburden detection system for sterile biopharmaceutical applications, according to LeCoque.
"Together, the combination of Charles River and Celsis will drive significant value for our combined customers' product-release testing needs across both sterile and non-sterile applications," he said in a statement.
According to Jay LeCoque, CEO, Celsis International, Ltd, Celsis is a complement to Charles River's Endotoxin and Microbial Detection group, creating the most comprehensive solution for rapid quality control testing of biopharmaceutical and consumer products. Specifically, the addition of Celsis, with its Advance II, Accel and Innovate systems will complement Charles River's recently introduced PTS-Micro, a rapid bioburden detection system for sterile biopharmaceutical applications, according to LeCoque.
"Together, the combination of Charles River and Celsis will drive significant value for our combined customers' product-release testing needs across both sterile and non-sterile applications," he said in a statement.